articleTop 10% cited
Clear Cell Carcinoma of the Ovary: A Distinct Histologic Type with Poor Prognosis and Resistance to Platinum-Based Chemotherapy in Stage III Disease
Gynecologic Oncology · 1996 · Vol. 60(3) · pp. 412–417
Barbara A. Goff✉(Harvard University)Ricardo Sáinz de la Cuesta(Harvard University)Howard G. Muntz(Woman's Cancer Foundation)Deborah Fleischhacker(Harvard University)Marit Ek(Woman's Cancer Foundation)Laurel W. Rice(Harvard University)Najmosama Nikrui(Harvard University)Hisham K. Tamimi(University of Washington)Joanna M. Cain(Woman's Cancer Foundation)Benjamin E. Greer(University of Washington)Arlan F. Fuller(Harvard University)
Ovarian cancer diagnosis and treatmentNeuroendocrine Tumor Research AdvancesEndometrial and Cervical Cancer TreatmentsMedicineChemotherapyStage (stratigraphy)DiseaseCarcinomaOvaryOncologyClear cell carcinomaInternal medicinePathology
MeSH terms
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinFemaleHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisSurvival AnalysisAdenocarcinoma, Clear Cell
Citations
358
FWCI
6.99
field-weighted impact
References
0
Percentile
97%
vs. same field & year
Citations per year
Cited by
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
Gynecologic Oncology · 2008 · 454 citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Annals of Oncology · 2019 · 1,130 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.